bubbles in fluid

ISS/ISE Package

1 minute read

Published: August 11th, 2020

Phastar was contracted to assist a global pharmaceutical company with their integrated summary of safety and efficacy for a regulatory submission. The work started with assisting the sponsor in defining an integration strategy for approximately 20 phase I studies, six phase II studies and their corresponding extension as well as three phase III studies and their long-term follow-up study. It involved defining a set of relevant analyses sets and reporting periods for both safety and efficacy analyses, ahead of writing up the analysis plans for the phase II pooled analyses, and phase II & III pooled analyses.

Complete the form below to read the full case study

Related articles

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

November 16th, 2026 1 minute read

When clinical development programs face quality concerns, resource shortages, or submission risks, sponsors need a pa...

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

November 16th, 2026 1 minute read

When a bioequivalence study fails to meet regulatory criteria, understanding why is critical for successful developme...

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

November 16th, 2026 1 minute read

Data Monitoring Committees play a vital role in safeguarding patient safety and supporting informed decision-making t...